AC   CVCL_5423
AS   CVCL_5590
SY   SUM-159-PT; SUM-159PT; SUM 159PT; SUM-159; SUM 159; SUM159; 159 PT; 159PT
DR   BTO; BTO:0004928
DR   CLO; CLO_0009918
DR   EFO; EFO_0001241
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-11134
DR   ArrayExpress; E-TABM-157
DR   BioGRID_ORCS_Cell_line; 1394
DR   BioSample; SAMN03472960
DR   cancercelllines; CVCL_5423
DR   Cell_Model_Passport; SIDM01452
DR   ChEMBL-Cells; CHEMBL4483124
DR   ChEMBL-Targets; CHEMBL4483269
DR   CLS; 305116
DR   Cosmic; 904389
DR   Cosmic; 1046944
DR   Cosmic; 1136380
DR   Cosmic; 1287924
DR   Cosmic; 1289412
DR   Cosmic; 1460240
DR   DepMap; ACH-001391
DR   EGA; EGAS00001000610
DR   GEO; GSM75170
DR   GEO; GSM217601
DR   GEO; GSM412074
DR   GEO; GSM412089
DR   GEO; GSM412092
DR   GEO; GSM412105
DR   GEO; GSM412114
DR   GEO; GSM412117
DR   GEO; GSM421890
DR   GEO; GSM474278
DR   GEO; GSM474279
DR   GEO; GSM476481
DR   GEO; GSM476482
DR   GEO; GSM476483
DR   GEO; GSM478318
DR   GEO; GSM478319
DR   GEO; GSM478323
DR   GEO; GSM478324
DR   GEO; GSM847434
DR   GEO; GSM847501
DR   GEO; GSM844707
DR   GEO; GSM844706
DR   GEO; GSM967817
DR   GEO; GSM967822
DR   GEO; GSM1008917
DR   GEO; GSM1053735
DR   GEO; GSM1172993
DR   GEO; GSM1214567
DR   GEO; GSM1401652
DR   GEO; GSM3145737
DR   IARC_TP53; 24342
DR   LINCS_HMS; 51083
DR   PharmacoDB; SUM159PT_1510_2019
DR   Progenetix; CVCL_5423
DR   PubChem_Cell_line; CVCL_5423
DR   SLKBase; 256
DR   Wikidata; Q54970841
RX   CelloPub=CLPUB00423;
RX   PubMed=10424408;
RX   PubMed=10604729;
RX   PubMed=10969801;
RX   PubMed=11044355;
RX   PubMed=12800145;
RX   PubMed=15677628;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=19593635;
RX   PubMed=21778573;
RX   PubMed=23151021;
RX   PubMed=23401782;
RX   PubMed=23601657;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=26735014;
RX   PubMed=28889351;
RX   PubMed=32416067;
RX   PubMed=32715085;
RX   PubMed=34320349;
RX   PubMed=35042871;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JWGray breast cancer cell line panel.
CC   Doubling time: 21.73 hours (JWGray panel).
CC   HLA typing: A*02:01,24:02; B*15:01,51:01; C*03:03,15:02 (PubMed=25960936).
CC   HLA typing: A*02:01,24:02; B*15:01,51:01; C*03:03,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (PubMed=15677628).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157_Arg158insLeu (c.472_473ins3); Zygosity=Unspecified (PubMed=16541312; PubMed=28889351).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: SUM152; Note=Occasionally.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
ST   Source(s): DepMap=ACH-001391; PubMed=25877200; PubMed=28889351
ST   Amelogenin: X
ST   CSF1PO: 10,11 (DepMap=ACH-001391)
ST   CSF1PO: 11 (PubMed=25877200; PubMed=28889351)
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 12,14 (PubMed=25877200)
ST   D18S51: 12,14,15 (DepMap=ACH-001391)
ST   D21S11: 28
ST   D3S1358: 11,16 (PubMed=25877200)
ST   D3S1358: 11,16,17 (DepMap=ACH-001391)
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 11,13
ST   FGA: 21,22
ST   Penta D: 9,11
ST   Penta E: 17
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C5161; Breast pleomorphic carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 38
RX   CelloPub=CLPUB00423;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010), Griffith University, Australia.
RX   PubMed=10424408; DOI=10.1023/A:1006135331912;
RA   Ignatoski K.M.W., Ethier S.P.;
RT   "Constitutive activation of pp125fak in newly isolated human breast
RT   cancer cell lines.";
RL   Breast Cancer Res. Treat. 54:173-182(1999).
RX   PubMed=10604729; DOI=10.1038/sj.bjc.6695007;
RA   Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A.H.,
RA   Kallioniemi O.-P., Ethier S.P.;
RT   "Molecular cytogenetic analysis of 11 new breast cancer cell lines.";
RL   Br. J. Cancer 81:1328-1334(1999).
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
RX   PubMed=11044355; DOI=10.1054/bjoc.2000.1458;
RA   Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C.,
RA   Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.;
RT   "Molecular cytogenetic analysis of breast cancer cell lines.";
RL   Br. J. Cancer 83:1309-1317(2000).
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
RX   PubMed=21778573; DOI=10.3233/BD-2010-0307;
RA   Chavez K.J., Garimella S.V., Lipkowitz S.;
RT   "Triple negative breast cancer cell lines: one tool in the search for
RT   better treatment of triple negative breast cancer.";
RL   Breast Dis. 32:35-48(2010).
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619.1-619.14(2012).
RX   PubMed=23401782; DOI=10.1155/2013/872743;
RA   Barnabas N., Cohen D.;
RT   "Phenotypic and molecular characterization of MCF10DCIS and SUM breast
RT   cancer cell lines.";
RL   Int. J. Breast Cancer 2013:872743.1-872743.16(2013).
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=26735014; DOI=10.1038/nature16508;
RA   Shu S.-K., Lin C.Y., He H.-S.H., Witwicki R.M., Tabassum D.P.,
RA   Roberts J.M., Janiszewska M., Huh S.J., Liang Y., Ryan J., Doherty E.,
RA   Mohammed H., Guo H., Stover D.G., Ekram M.B., Brown J., D'Santos C.,
RA   Krop I.E., Dillon D., McKeown M.R., Ott C., Qi J., Ni M., Rao P.K.,
RA   Duarte M., Wu S.-Y., Chiang C.-M., Anders L., Young R.A., Winer E.,
RA   Letai A.G., Barry W.T., Carroll J.S., Long H., Brown M.A., Liu X.-L.S.,
RA   Meyer C.A., Bradner J.E., Polyak K.;
RT   "Response and resistance to BET bromodomain inhibitors in
RT   triple-negative breast cancer.";
RL   Nature 529:413-417(2016).
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
RX   PubMed=32416067; DOI=10.1016/j.molcel.2020.04.027;
RA   Shu S.-K., Wu H.-J., Ge J.Y., Zeid R., Harris I.S., Jovanovic B.,
RA   Murphy K., Wang B.-B., Qiu X.-T., Endress J.E., Reyes J., Lim K.,
RA   Font-Tello A., Syamala S., Xiao T.-F., Reddy Chilamakuri C.S.,
RA   Papachristou E.K., D'Santos C., Anand J., Hinohara K., Li W.,
RA   McDonald T.O., Luoma A., Modiste R.J., Nguyen Q.-D., Michel B.,
RA   Cejas P., Kadoch C., Jaffe J.D., Wucherpfennig K.W., Qi J., Liu X.-L.S.,
RA   Long H., Brown M.A., Carroll J.S., Brugge J.S., Bradner J.E., Michor F.,
RA   Polyak K.;
RT   "Synthetic lethal and resistance interactions with BET bromodomain
RT   inhibitors in triple-negative breast cancer.";
RL   Mol. Cell 78:1096-1113.e8(2020).
RX   PubMed=32715085; DOI=10.1038/s41523-020-0173-z;
RA   Ethier S.P., Guest S.T., Garrett-Mayer E., Armeson K., Wilson R.C.,
RA   Duchinski K., Couch D., Gray J.W., Kappler C.S.;
RT   "Development and implementation of the SUM breast cancer cell line
RT   functional genomics knowledge base.";
RL   NPJ Breast Cancer 6:30.1-30.14(2020).
RX   PubMed=34320349; DOI=10.1016/j.celrep.2021.109441;
RA   Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K.,
RA   Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L.,
RA   Leite de Oliveira R., Wessels L.F.A., Bernards R.;
RT   "The cancer SENESCopedia: a delineation of cancer cell senescence.";
RL   Cell Rep. 36:109441.1-109441.22(2021).
RX   PubMed=35042871; DOI=10.1038/s41523-021-00379-6;
RA   Rypens C., Bertucci F., Finetti P., Robertson F.M., Fernandez S.V.,
RA   Ueno N.T., Woodward W.A., Van Golen K., Vermeulen P., Dirix L.,
RA   Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.;
RT   "Comparative transcriptional analyses of preclinical models and
RT   patient samples reveal MYC and RELA driven expression patterns that
RT   define the molecular landscape of IBC.";
RL   NPJ Breast Cancer 8:12.1-12.12(2022).